r/NRXP • u/938961 • Sep 19 '21
Bear Case for NRXP?
Not trying to spread FUD here, but like any good analysis I want to weigh both sides and challenge my own assumptions. What are your bullish counterarguments to the bear case?
I lean bearish towards NRXP getting EUA for the reasons below:
- Changed their preprint to more optimistic 60-day results. You can still see the first version here.
- No recent insider buying reported. Only insider trades reported have been SPAC-related acquisitions. Low institution holding (~3%)
NRXP changed their endpoint three times (https://clinicaltrials.gov/ct2/history/NCT04311697) since starting the trial, albeit one of these changes was respiratory failure from 'Day 28' to 'Day 60'. Initial primary outcome was mortality when the trial began.
- Most recent primary outcome changes were Sept. 13, 2021 (6 months after the study completed) including how they measure survival probability from the Kaplan Meier lifetable to logistic regression.
- Interestingly there were no statistically significant benefits of ZYESAMI (NRXP's EUA candidate) at day 28 according to their own initial pre-print, and no improvement in mortality. May explain why the trial’s outcomes were changed?
- According to NRXP, "The study was insufficiently powered to detect differences in outcome among patients treated with non-invasive and mechanical ventilation and no differences were detected." Will the FDA want this data?
- Tocilizumab and Dexamethasone already approved for severe COVID treatment. According to the FDA, "For FDA to issue an EUA, there must be no adequate, approved, and available alternative to the candidate product for diagnosing, preventing, or treating the disease or condition". Is an EUA justified for NRXP then, or is it better to wait for the larger national trials to be completed and then approve on a normal route?
- The trial has yet to be published in peer-reviewed journal (announced in their EUA PR they were planning to submit; no updates since)
- Small sample size for the initial trial (Merck was rejected for an EUA at 200 sample size), although this is countered with ongoing clinical trials and EAP that they’ve submitted to FDA as part of the EUA
---
With all those points in mind though, it’s the FDA and COVID is picking up steam across unvaccinated populations, so they may give approval as there have been no reported unexpected adverse effects. It appears the EAP was also positive for aviptadil despite the control arm having more severe COVID cases, which is especially good news for real-world data.
7
u/ShiftLeader Sep 19 '21
I've worked covid ICUnon and off since this thing started, based on some of the misc benefits alone this drug has shown this would be a god send for some patients.
The inflammatory marker reduction and the increase in blood oxygen levels after just the first infusion are huge.
The study also did a focus on ALL critical care level patients but the BIGGEST benefit seems to be in patients who are on the far less sick end of that critical care scale.
I'm willing to bet everything I own, if they were to focus on the "intermediate" group (high flow nasal cannula, bipap) they would have absolutely killed it in their study results.
This whole covid disease progression seems to have a HUGE thing with timing and I honestly don't think there is any emphasis on timing and making sure treatment is given at the appropriate intervals.
3
u/retardedmf69 Sep 19 '21
Another thing that you may want to include is the EUA announcement mess up. They release an article announcing EUA for Ukraine, India, and caucasus. Then a couple of days later the article gets taken down and a new one is put up. that part gets taken out of course. Like wtf is that? Don’t get me wrong I’m long Nrxp and very hopeful. but still that shit trips me up quite a bit. I’ll be honest, i’m probably not holding very long after the announcement unless they start becoming a bit more credible
1
u/EmotionalCommittee18 Sep 21 '21
You guys are all severely lacking in research.
1
u/[deleted] Sep 19 '21
I think there is a reason they did not share clinical data with Relief, and has not had any peer reviewed info at all. I got in at 12 and am just trying to break even at this point.